Overview

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Status:
RECRUITING

Trial end date:
2031-12-01

Target enrollment:

Participant gender:

Summary

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.

Phase:

PHASE2

Details

Lead Sponsor:

Grupo Espaol de Linfomas y Transplante Autlogo de Mdula sea

Collaborators:

AbbVie
Evidenze Health Espaa (CRO)
Incyte Corporation

Treatments:

Lenalidomide
tafasitamab